Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology

Pain Medicine

Volumn 4, Issue 2, 2003, Pages 206-210

  Jabbari, Bahman ^a,b   Maher, Neil ^a   Difazio, Marc P ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Botox; Botulinum toxin A; Pain; Spinal cord

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BOTULINUM TOXIN A; ERGOT DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PROPRANOLOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ALLODYNIA; ANALGESIC ACTIVITY; ARTICLE; BURNING SENSATION; CASE REPORT; CERVICAL SPINAL CORD; DERMATOME; DRUG EFFECT; DYSESTHESIA; FEMALE; FOLLOW UP; HUMAN; MIGRAINE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; SKIN SENSITIVITY; SPINAL CORD DISEASE; SPINAL CORD TUMOR; STROKE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; DRUG EFFICACY; PAIN; STATISTICAL SIGNIFICANCE;

ADULT; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN; SPINAL CORD DISEASES; TREATMENT OUTCOME;

EID: 0042632941     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4637.2003.03013.x     Document Type: Article

References (25)

1. Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-7.
2. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-80.
3. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-17.
4. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59:65-9.
5. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: A pilot study. J Rheumatol 2000;27:481-4.
6. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000;40:445-50.
7. Foster L, Clapp L, Erickson M, et al. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001;56:1290-3.
8. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38:245-58.
9. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000;44:106-9.
10. Cui ML, Khanijou S, Rubino J, et al. Botulinum toxin type A inhibits the inflammatory pain in the rat formalin model. Poster 246.2 presented at the Society for Neuroscience Annual Meeting, New Orleans, LA; 2000.
11. Sipski ML, Hendler S, DeLisa JA. Rehabilitation of patients with spinal cord disease. Neurol Clin 1991;9:704-25.
12. Friedman AH, Nashold BS Jr. DREZ lesions for relief of pain related to spinal cord injury. J Neurosurg 1986;65:465-9.
13. Basbaum AI, Jessell TM. The perception of pain. In: Kandel ER, Schwartz JH, Jessell TH, editors. Principles of neuronal science. New York: McGraw Hill Publishers; 2000:480-1.
14. Filippi GM, Errico P, Santarelli R, et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400-4.
15. Willis WD, Westlund KN. Neuroanatomy of the pain system and the pathways that modulate pain. J Clin Neurophysiol 1997;14:2-31.
16. Woolf CJ, Shortland P, Reynolds M, et al. Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy. J Comp Neurol 1995;360:121-34.
17. Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature 1965; 206:588-91.
18. McLachlan EM, Janig W, Devor M, et al. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993;363:543-6.
19. Sanchez-Prieto J, Sihra TS, Evans D, et al. Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes. Eur J Biochem 1987;165:675-81.
20. Mills CD, Johnson KM, Hulsebosch CE. Group I metabotropic glutamate receptors in spinal cord injury: Roles in neuroprotection and the development of chronic central pain. J Neurotrauma 2002;19:23-42.
21. Harrington JF, Messier AA, Bereiter D, et al. Herniated lumbar disc material as a source of free glutamate available to affect pain signals through the dorsal root ganglion. Spine 2000;25:929-36.
22. Alfredson H, Lorentzon R. Chronic tendon pain: No signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment? Curr Drug Targets 2002;3:43-54.
23. Roberts WJ. A hypothesis on the physiological basis for causalgia and related pains. Pain 1986;24:297-311.
24. Wieggand H, Erdman G, Welhoner HH. 125 I-labeled botulinum toxin A neurotoxin: Pharmacokinetics in cats after intramuscularly injection. Arch Pharmacol 1976;292:161-5.
25. Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord 1993;8:33-7.